1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.
Janani Rangaswami, MD, FAHA
Advertisement
Janani Rangaswami, MD, FAHA, a nephrologist with expertise in cardiovascular- kidney medicine; Professor of Medicine, George Washington University, Washington DC; Co-chair, Scientific Advisory Group of the AHA's presidential advisory on CKM Health.
Articles by Janani Rangaswami, MD, FAHA
CKM syndrome affects nearly 90% of US adults, highlighting the need to manage cardiovascular, kidney, and metabolic risk together.
Advertisement